Category: Bio/Pharma/CRO
Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A
People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a lack of treatment guidelines1,2 New data indicate that Hemlibra has a favourable safety profile in people with moderate or mild haemophilia A without factor... Read more
New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free survival improvement for the combination compared with Tecentriq alone CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell... Read more
Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)
Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year.1 The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study. This new test expands Roche’s... Read more
Waters and University of Delaware Announce Bioprocessing Innovation Partnership, Plan 2022 Opening of Immerse Delaware Lab
Partnership will focus on developing analytical solutions to better characterize bioprocesses towards improved quality, yields and efficiency News Summary: Waters and University of Delaware announce a multi-year collaboration to develop technology for analytical characterization of manufacturing processes for biologics and novel modalities. Waters’ staff and university researchers will co-locate at Immerse™ Delaware, an Innovation and... Read more
PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis
Flagship product from Honeycomb Biotechnologies advances single-cell profiling by enabling scientists to capture, store and study fragile cell types WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 18, 2021– PerkinElmer, Inc. (NYSE: PKI) and Honeycomb Biotechnologies, Inc., announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis. The HIVE solution leverages a... Read more
PerkinElmer Collaborates With Leading Life Science Incubators LabCentral and MBC BioLabs to Help Further Drug Discovery
Will provide automated protein characterization, cell imaging and cell counting technologies, along with expertise and training October 14, 2021 WHAT: PerkinElmer, Inc. a global leader committed to innovating for a healthier world, today announced it is collaborating with leading life science incubators LabCentral in Boston, Massachusetts and MBC BioLabs in San Francisco, California to provide... Read more
PerkinElmer Introduces Next Generation Cell Image Analysis and Management Software Platform to Help Streamline Drug Discovery Decision Making
Signals Image Artist helps scientists process and analyze 3D cell imaging, phenotypic and cell painting data in hours vs. days or weeks October 4, 2021 WHAT: PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced the launch of Signals Image Artist™ software, a next generation image analysis and management... Read more
Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline Clinical data complement previous findings in hospitalised setting, including from United Kingdom (UK) University of Oxford-led RECOVERY trial Basel, 30 September 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more